Clinical Trial

ATATcH Alternating Treatment Plans for Advanced Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-04-27; most recent amendment 2026-04-25.
Status change: Not Yet Recruiting → Recruiting 2022-10-13
Trial Details
NCT Number NCT05358548
Lead Sponsor Rutgers, The State University of New Jersey
Conditions Head and Neck Cancer, Lung Cancer
Enrollment 150 participants
Start Date 2022-04-28
Primary Completion 2027-05-01 (estimated)
Study Completion 2028-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-30